Chemomab Therapeutics Ltd. (CMMB)
| Market Cap | 125.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.07M |
| Shares Out | 216.27M |
| EPS (ttm) | -0.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,051,699 |
| Open | 10.50 |
| Previous Close | 10.02 |
| Day's Range | 10.36 - 12.46 |
| 52-Week Range | 8.46 - 2,700.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 15, 2021 |
About CMMB
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Financial Performance
Financial StatementsNews
Chemomab Therapeutics Announces Collaboration with Leeds University to Further Elucidate the Role of CCL24 in Vascula...
TEL AVIV, Israel, Sept. 27, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd.
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
TEL AVIV, Israel, Sept. 2, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd.
Chemomab to Participate in Upcoming September Investor Conferences
TEL AVIV, Israel, Sept. 1, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd.
Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update
TEL AVIV, Israel, Aug. 13, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibros...
Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III
TEL AVIV, Israel and SEATTLE, June 23, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeuti...
Chemomab Therapeutics Is Heating Up And Could See A Move Soon
Chemomab Therapeutics LTD. (NASDAQ: CMMB) shares are trading higher Friday as retail traders continue to push stocks higher.
Chemomab Announces Poster Presentation at the International Liver Congress 2021 (EASL)
TEL AVIV, Israel, June 10, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibro...
Chemomab Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update
TEL-AVIV, Israel, May 13, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosi...
Chemomab to Present at Oppenheimer's Virtual Rare and Orphan Disease Summit
TEL AVIV, Israel, May 12, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosi...
Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)
TEL-AVIV, Israel, April 26, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibr...
Chemomab Announces Four New Appointments to the Board of Directors and Completion of PIPE Financing
TEL-AVIV, Israel, March 29, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibr...
Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing
Anchiano s hareholders approve all resolutions at shareholder meeting
Why Immunovant, Anchiano, OpGen Are Rallying Today
Immunovant, Inc. (NASDAQ: IMVT), Anchiano Therapeutics Ltd. (NASDAQ: ANCN) and OpGen, Inc. (NASDAQ: OPGN) are among the biggest healthcare gainers on Monday.
ANCN Stock: Speculation Around Investor Letter Sends Anchiano Therapeutics Soaring
Anchiano Therapeutics (ANCN) stock is rocketing higher on Monday after a shareholder letter caught the interest of investors. The post ANCN Stock: Speculation Around Investor Letter Sends Anchiano Thera...
ANCN Stock: 10 Things to Know as Anchiano Therapeutics Rockets Higher
ANCN stock is an early stage company engaged in clinical trials for rare liver, lung and skin diseases with no FDA-approved options now. The post ANCN Stock: 10 Things to Know as Anchiano Therapeutics R...
SHAREHOLDER ALERT: WeissLaw LLP Reminds CHNG, CPAH, CATM, and ANCN Shareholders About Its Ongoing Investigations
NEW YORK, Feb. 4, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or ...
Lifshitz Law Firm, P.C. Announces Investigation of ANCN, BEAT, HMSY, SNCA, SPWH, TCP, TRP, TLRY, and APHA
NEW YORK, Dec. 24, 2020 /PRNewswire/ -- Anchiano Therapeutics Ltd. (NASDAQ: ANCN) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger o...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd.
NEW YORK, Dec. 15, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Anchiano Therapeutics Ltd. ("Anchiano" ...
ANCN Stock: Why Anchiano Therapeutics Stock Is Blasting Higher Today
Anchiano Therapeutics (ANCN) stock is soaring higher on Tuesday following news of a merger with Chemomab that will bring major changes. The post ANCN Stock: Why Anchiano Therapeutics Stock Is Blasting H...
6 Health Care Stocks Trading With Low Price-Earnings Ratios
As of Dec. 10, the GuruFocus All-in-One Screener, a Premium feature, found that the following health care companies have low price-earnings ratios and are owned by gurus. While some of them are great va...
All You Need to Know About Anchiano Therapeutics Ltd. Sponsored ADR (ANCN) Rating Upgrade to Buy
Anchiano Therapeutics Ltd. Sponsored ADR (ANCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Anchiano Appoints Steve DiPalma as Chief Financial Officer
CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer. Mr. DiPa...
Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders
CAMBRIDGE, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) announced today that its board of directors approved the record date for the Company’s 202...